QJM Advance Access originally published online on January 17, 2008
QJM 2008 101(3):243-245; doi:10.1093/qjmed/hcm147
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Another dangerous combination for hypoglycemic coma: concurrent use of sibutramine and lorazepam
| The first 10% of the full text of this article appears below. |
Sir,
With increasing demands to treat obesity in both medical and psychological aspects, many drugs are developed to lower human body weight. Those widely used anti-obesity drugs, such as olistat and sibutramine, are generally safe. But serious adverse effects could be developed when it is concurrently used with other medications. We report a patient who developed hypoglycemic coma due to concurrent use of sibutramine and lorazepam.
A 32-year-old woman presented to the emergency department because of disturbed consciousness
Department of Emergency Medicine
Tri-Service General Hospital
National Defense Medical Center
Taipei
Taiwan
Republic of China
email: doc50024@ndmctsgh.edu.tw